Navigation Links
Inoperable Colon Cancer Responds to New Treatment
Date:6/16/2009

Individuals from 26 U.S. states and four other countries have been among the first to use NeoPlas Innovation's new protocol.

Nashville, Tenn. (Vocus) June 16, 2009 -- With an extensive, inoperable colon cancer and few options available, a Tennessee patient is seeing his cancer steadily regressing on a new outpatient treatment. Individuals from 26 U.S. states and four other countries have been among the first to use NeoPlas Innovation's new protocol. The Tennessee patient's early results mirror their successes in battling colon cancer and other very aggressive malignancies.

The most recent colon cancer patient is a man in his late fifties who had an extensive cancer of the lower colon diagnosed in early 2008. Initially his doctors recommended surgical resection in an operation that would have removed all the organs of his lower abdomen and pelvis; however, it was determined that he would be unlikely to survive the procedure. Chemotherapy was tried, but was ineffective. He visited NeoPlas Innovation's Nashville clinic in the spring of 2009 and began the new outpatient treatment.

Two months later, CT scans have shown that the cancer has regressed dramatically. The patient's symptoms are resolving in step with the response, with improvements in appetite and digestion and the regaining of lost weight. NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell commented, "These are results from one patient, so no conclusions can be drawn. But this is consistent with the favorable responses we're seeing in the great majority of our patients, including those with colon cancer." The protocol is offered for qualifying patients with colon cancer, renal (kidney) cancer, pancreatic cancer, melanoma, mesothelioma and certain sarcomas. It can be considered for other patients on a case-by-case basis.

The new treatment is an off-label combination of two existing medicines: lovastatin, typically used as a cholesterol lowering agent, and interferon. According to Dr. Cantrell, "The key to moving from the lab to success in humans has been taking a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, the results have been surprising." NeoPlas Innovation patients often have seen the arrest of their cancers' growth and spread in as few as eight weeks of treatment. In many cases, such as this one, patients have experienced active regression of tumors.

The medicines used have the advantage of being safe and well tolerated. Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.

NeoPlas Innovation's web site, www.neoplas.org, provides complete information and an interactive screening tool for patients who are considering this treatment. The clinic can be reached at (615) 371-8100.

For an interview with Dr. Cantrell, call 615-371-8100.

###

Read the full story at http://www.prweb.com/releases/Colon_Cancer/Cancer_Treatment/prweb2544534.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. New Treatment Option at The Sarah Cannon Cancer Center Provides Hope for Inoperable Tumors
2. Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient
3. St. Jude study offers new hope for children with kidney tumors deemed inoperable
4. For Some, Virtual Colonoscopy May Be Just As Good
5. VA Faces Questions Over Tainted Colonoscopies
6. For Some, Virtual Colonography May Be Just As Good
7. Racial Clusters Seem to Affect Access to Colon Care
8. Colonoscopy Risks Increase With Age and Illness
9. Weight May Affect Colonoscopy Success
10. Deep Sleep May Improve Colonoscopy Results
11. Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Inoperable Colon Cancer Responds to New Treatment
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology: